Clinical trial
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed…
NCT00002865 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00002865 |
|---|---|
| Title | High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia |
| Official title | HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Radiation |
| Interventions | filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate and 4 more |
| Enrollment | 25 |
| Start date | Apr 1, 1995 |
| Primary completion | Jun 1, 2000 |
| Completion | Aug 1, 2001 |
| First posted | Aug 11, 2004 |
| Last update posted | Aug 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: